Impedimed Ltd - Asset Resilience Ratio
Impedimed Ltd (IPD) has an Asset Resilience Ratio of 46.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Impedimed Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Impedimed Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Impedimed Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Impedimed Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Impedimed Ltd (IPD) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.71 Million | 46.15% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$17.71 Million | 46.15% |
Asset Resilience Insights
- Very High Liquidity: Impedimed Ltd maintains exceptional liquid asset reserves at 46.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Impedimed Ltd Industry Peers by Asset Resilience Ratio
Compare Impedimed Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.29% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
DRTECH Corporation
KQ:214680 |
Medical Devices | 5.18% |
|
Novacyt
PA:ALNOV |
Medical Devices | 0.02% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
Annual Asset Resilience Ratio for Impedimed Ltd (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Impedimed Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 52.04% | AU$21.68 Million ≈ $15.34 Million |
AU$41.66 Million ≈ $29.48 Million |
+12.90pp |
| 2024-06-30 | 39.14% | AU$18.39 Million ≈ $13.01 Million |
AU$46.99 Million ≈ $33.25 Million |
+19.42pp |
| 2023-06-30 | 19.71% | AU$13.55 Million ≈ $9.59 Million |
AU$68.74 Million ≈ $48.64 Million |
-33.59pp |
| 2022-06-30 | 53.30% | AU$31.29 Million ≈ $22.14 Million |
AU$58.70 Million ≈ $41.53 Million |
+19.68pp |
| 2021-06-30 | 33.62% | AU$11.50 Million ≈ $8.14 Million |
AU$34.20 Million ≈ $24.20 Million |
+7.07pp |
| 2020-06-30 | 26.55% | AU$8.78 Million ≈ $6.21 Million |
AU$33.06 Million ≈ $23.39 Million |
-9.61pp |
| 2019-06-30 | 36.16% | AU$8.16 Million ≈ $5.78 Million |
AU$22.58 Million ≈ $15.98 Million |
-31.92pp |
| 2018-06-30 | 68.08% | AU$28.30 Million ≈ $20.02 Million |
AU$41.57 Million ≈ $29.41 Million |
-5.30pp |
| 2017-06-30 | 73.38% | AU$47.22 Million ≈ $33.41 Million |
AU$64.34 Million ≈ $45.53 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$90.57 Million ≈ $64.08 Million |
-- |
| 2012-06-30 | 0.16% | AU$31.00K ≈ $21.93K |
AU$19.61 Million ≈ $13.88 Million |
+0.02pp |
| 2011-06-30 | 0.14% | AU$31.00K ≈ $21.93K |
AU$22.80 Million ≈ $16.14 Million |
-0.08pp |
| 2008-06-30 | 0.21% | AU$31.00K ≈ $21.93K |
AU$14.52 Million ≈ $10.27 Million |
-0.47pp |
| 2007-06-30 | 0.68% | AU$148.00K ≈ $104.72K |
AU$21.79 Million ≈ $15.42 Million |
-- |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more